|
Market Closed -
Euronext Paris
03:55:00 11/11/26 am AEDT
|
5-day change | 1st Jan Change | ||
| 8.060 EUR | -6.92% |
|
-12.02% | -52.17% |
| 20/10 | Sensorion Announces Appointment of Peter Weber as Chief Medical Officer, Effective November 2, 2026 | CI |
| 19/10 | Sensorion rallies after appointment of chief medical officer |  |
| Market Cap | 83.06M 92.62M 76.55M 69.52M 132M 8.68B 135M 917M 365M 4.65B 348M 340M 14.71B | P/E 2026 * |
-2.41x | P/E 2027 * | -3.6x |
|---|---|---|---|---|---|
| Enterprise Value | 9.06M 10.1M 8.35M 7.58M 14.35M 947M 14.75M 99.95M 39.82M 507M 37.9M 37.1M 1.6B | EV / Sales 2026 * |
1.94x | EV / Sales 2027 * | 0.51x |
| Free-Float |
65.24% | Yield 2026 * |
-
| Yield 2027 * | - |
| Markets | Quality | ||
|---|---|---|---|
Euronext Paris
| ALSEN | Real-time | |
Börse Stuttgart
| RFM | Delayed | |
|
Börse Stuttgart
| RFM | Delayed | |
|
CBOE
| Real-time | ||
|
CBOE
| Real-time | ||
|
Deutsche Boerse AG
| RFM | Delayed | |
|
Boerse Muenchen
| RFM | Real-time | |
|
CBOE
| Real-time | ||
|
Boerse Muenchen
| RFM | Real-time | |
|
CBOE
| Real-time | ||
|
Tradegate
| RFM | Real-time |
| 1 day | -6.92% | ||
| 1 week | -12.02% | ||
| Current month | -6.71% | ||
| 1 month | +37.78% | ||
| 3 months | -44.22% | ||
| 6 months | -62.51% | ||
| Current year | -52.17% |
| 1 week | 8.04 |  | 9.49 |
| 1 month | 5.25 | | 10.26 |
| Current year | 5.25 | | 40.4 |
| 1 year | 5.25 | | 40.4 |
| 3 years | 5.25 | | 52 |
| 5 years | 5.25 | | 114.5 |
| 10 years | 5.25 | | 387 |
| Manager | Title | Age | Since |
|---|---|---|---|
Frédéric Chéreau
CEO | Chief Executive Officer | 59 | 01/06/2026 |
Louis Arcudi
DFI | Director of Finance/CFO | 65 | 07/10/2026 |
Bernd Schmidt
CTO | Chief Tech/Sci/R&D Officer | - | 11/12/2023 |
| Director | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | - | 09/03/2015 | |
Julien Miara
BRD | Director/Board Member | 43 | - |
Khalil Barrage
CHM | Chairman | 61 | 30/03/2023 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 6/2/26 | Redmile Biopharma Investments III LP
| Buy | Company | 18,928,571 | 6.2956% | |
| 31/1/26 | Sofinnova Partners SAS
| Buy | Company | 10,714,285 | 3.5636% | |
| 18/4/24 | Redmile Biopharma Investments III LP
| Buy | Company | 2,781,914 | 1.0091% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -6.92% | -12.02% | -54.46% | -71.67% | 99.97M | |
| +0.01% | +8.40% | +58.48% | +69.01% | 68.22B | |
| +1.22% | +10.23% | +18.35% | +87.67% | 59.82B | |
| +0.24% | +1.97% | +24.62% | +94.87% | 56.07B | |
| +1.60% | +17.36% | +32.51% | +123.69% | 47.67B | |
| -1.32% | +6.47% | +30.74% | +43.37% | 45.95B | |
| -3.54% | +2.60% | +216.44% | +864.34% | 43.29B | |
| -3.33% | +5.73% | +23.28% | +47.32% | 35.66B | |
| -2.19% | -3.16% | +93.83% | +63.14% | 34.73B | |
| +2.92% | +9.31% | -37.01% | +410.20% | 25.47B | |
| Average | -1.13% | +4.26% | +40.68% | +173.19% | 42B | |
| Weighted average by Cap. | -0.41% | +5.40% | +52.62% | +179.62% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 4.66M 5.2M 4.3M 3.9M 7.39M 487M 7.59M 51.45M 20.5M 261M 19.51M 19.1M 826M | 15.92M 17.75M 14.67M 13.32M 25.22M 1.66B 25.92M 176M 69.99M 892M 66.62M 65.21M 2.82B |
| Net income | -36M -40.14M -33.18M -30.13M -57.02M -3.76B -58.62M -397M -158M -2.02B -151M -147M -6.37B | -28.79M -32.1M -26.53M -24.09M -45.6M -3.01B -46.87M -318M -127M -1.61B -120M -118M -5.1B |
| Net Debt | -74M -82.52M -68.2M -61.94M -117M -7.74B -120M -817M -325M -4.14B -310M -303M -13.1B | -75M -83.63M -69.12M -62.77M -119M -7.84B -122M -828M -330M -4.2B -314M -307M -13.28B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 10/11/26 | EUR 8.060 | -6.92% | 15,216 |
| 09/11/26 | EUR 8.659 | -2.05% | 7,760 |
| 06/11/26 | EUR 8.840 | -4.20% | 6,174 |
| 05/11/26 | EUR 9.228 | +0.30% | 13,497 |
| 04/11/26 | EUR 9.200 | -0.55% | 9,287 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
- Stock Market
- Stocks
- ALSEN Stock
Select your edition
All financial news and data tailored to specific country editions
